Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis

Figure 1

Time-to-event: 12-week confirmed disability progression of real-world pre-ocrelizumab population () and the ORATORIO placebo arm. ORATORIO data were adapted from the original ORATORIO publication of Montalban et al. [12].